Literature DB >> 24813991

Time-resolved FRET reveals the structural mechanism of SERCA-PLB regulation.

Xiaoqiong Dong1, David D Thomas2.   

Abstract

We have used time-resolved fluorescence resonance energy transfer (TR-FRET) to characterize the interaction between phospholamban (PLB) and the sarcoplasmic reticulum (SR) Ca-ATPase (SERCA) under conditions that relieve SERCA inhibition. Unphosphorylated PLB inhibits SERCA in cardiac SR, but inhibition is relieved by either micromolar Ca(2+) or PLB phosphorylation. In both cases, it has been proposed that inhibition is relieved by dissociation of the complex. To test this hypothesis, we attached fluorophores to the cytoplasmic domains of SERCA and PLB, and reconstituted them functionally in lipid bilayers. TR-FRET, which permitted simultaneous measurement of SERCA-PLB binding and structure, was measured as a function of PLB phosphorylation and [Ca(2+)]. In all cases, two structural states of the SERCA-PLB complex were resolved, probably corresponding to the previously described T and R structural states of the PLB cytoplasmic domain. Phosphorylation of PLB at S16 completely relieved inhibition, partially dissociated the SERCA-PLB complex, and shifted the T/R equilibrium within the bound complex toward the R state. Since the PLB concentration in cardiac SR is at least 10 times that in our FRET measurements, we calculate that most of SERCA contains bound phosphorylated PLB in cardiac SR, even after complete phosphorylation. 4 μM Ca(2+) completely relieved inhibition but did not induce a detectable change in SERCA-PLB binding or cytoplasmic domain structure, suggesting a mechanism involving structural changes in SERCA's transmembrane domain. We conclude that Ca(2+) and PLB phosphorylation relieve SERCA-PLB inhibition by distinct mechanisms, but both are achieved primarily by structural changes within the SERCA-PLB complex, not by dissociation of that complex.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FRET; Phospholamban; Phosphorylation; SERCA

Mesh:

Substances:

Year:  2014        PMID: 24813991      PMCID: PMC4054823          DOI: 10.1016/j.bbrc.2014.04.166

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  44 in total

1.  Defining the molecular components of calcium transport regulation in a reconstituted membrane system.

Authors:  Laxma G Reddy; Razvan L Cornea; Deborah L Winters; Edward McKenna; David D Thomas
Journal:  Biochemistry       Date:  2003-04-22       Impact factor: 3.162

2.  Phosphomimetic mutations increase phospholamban oligomerization and alter the structure of its regulatory complex.

Authors:  Zhanjia Hou; Eileen M Kelly; Seth L Robia
Journal:  J Biol Chem       Date:  2008-08-16       Impact factor: 5.157

3.  Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum.

Authors:  P James; M Inui; M Tada; M Chiesi; E Carafoli
Journal:  Nature       Date:  1989-11-02       Impact factor: 49.962

4.  Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers.

Authors:  R L Cornea; L R Jones; J M Autry; D D Thomas
Journal:  Biochemistry       Date:  1997-03-11       Impact factor: 3.162

5.  Mapping the interaction surface of a membrane protein: unveiling the conformational switch of phospholamban in calcium pump regulation.

Authors:  J Zamoon; F Nitu; C Karim; D D Thomas; G Veglia
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

Review 6.  Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions.

Authors:  Alicia Mattiazzi; Cecilia Mundiña-Weilenmann; Chu Guoxiang; Leticia Vittone; Evangelia Kranias
Journal:  Cardiovasc Res       Date:  2005-10-13       Impact factor: 10.787

7.  Sarcolipin is a newly identified regulator of muscle-based thermogenesis in mammals.

Authors:  Naresh C Bal; Santosh K Maurya; Danesh H Sopariwala; Sanjaya K Sahoo; Subash C Gupta; Sana A Shaikh; Meghna Pant; Leslie A Rowland; Eric Bombardier; Sanjeewa A Goonasekera; A Russell Tupling; Jeffery D Molkentin; Muthu Periasamy
Journal:  Nat Med       Date:  2012-09-09       Impact factor: 53.440

8.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.

Authors:  Yoshitaka Iwanaga; Masahiko Hoshijima; Yusu Gu; Mitsuo Iwatate; Thomas Dieterle; Yasuhiro Ikeda; Moto-o Date; Jacqueline Chrast; Masunori Matsuzaki; Kirk L Peterson; Kenneth R Chien; John Ross
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

9.  (Iodoacetamido)fluorescein labels a pair of proximal cysteines on the Ca2+-ATPase of sarcoplasmic reticulum.

Authors:  J E Bishop; T C Squier; D J Bigelow; G Inesi
Journal:  Biochemistry       Date:  1988-07-12       Impact factor: 3.162

10.  Ca(2+)/H (+) exchange, lumenal Ca(2+) release and Ca (2+)/ATP coupling ratios in the sarcoplasmic reticulum ATPase.

Authors:  Giuseppe Inesi; Francesco Tadini-Buoninsegni
Journal:  J Cell Commun Signal       Date:  2013-12-04       Impact factor: 5.782

View more
  20 in total

1.  Atomic-level mechanisms for phospholamban regulation of the calcium pump.

Authors:  L Michel Espinoza-Fonseca; Joseph M Autry; G Lizbeth Ramírez-Salinas; David D Thomas
Journal:  Biophys J       Date:  2015-04-07       Impact factor: 4.033

2.  Fluorescence lifetime plate reader: resolution and precision meet high-throughput.

Authors:  Karl J Petersen; Kurt C Peterson; Joseph M Muretta; Sutton E Higgins; Gregory D Gillispie; David D Thomas
Journal:  Rev Sci Instrum       Date:  2014-11       Impact factor: 1.523

3.  Acute inotropic and lusitropic effects of cardiomyopathic R9C mutation of phospholamban.

Authors:  Neha Abrol; Pieter P de Tombe; Seth L Robia
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

4.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

5.  Amplitude of the actomyosin power stroke depends strongly on the isoform of the myosin essential light chain.

Authors:  Piyali Guhathakurta; Ewa Prochniewicz; David D Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

6.  Dynamics-Driven Allostery Underlies Ca2+-Mediated Release of SERCA Inhibition by Phospholamban.

Authors:  Olga N Raguimova; Rodrigo Aguayo-Ortiz; Seth L Robia; L Michel Espinoza-Fonseca
Journal:  Biophys J       Date:  2020-09-24       Impact factor: 4.033

Review 7.  Chasing cardiac physiology and pathology down the CaMKII cascade.

Authors:  Alicia Mattiazzi; Rosana A Bassani; Ariel L Escobar; Julieta Palomeque; Carlos A Valverde; Martín Vila Petroff; Donald M Bers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

8.  Protein docking and steered molecular dynamics suggest alternative phospholamban-binding sites on the SERCA calcium transporter.

Authors:  Rebecca F Alford; Nikolai Smolin; Howard S Young; Jeffrey J Gray; Seth L Robia
Journal:  J Biol Chem       Date:  2020-06-17       Impact factor: 5.157

9.  Resolved Structural States of Calmodulin in Regulation of Skeletal Muscle Calcium Release.

Authors:  Megan R McCarthy; Yahor Savich; Razvan L Cornea; David D Thomas
Journal:  Biophys J       Date:  2020-01-21       Impact factor: 4.033

10.  S100A1 Protein Does Not Compete with Calmodulin for Ryanodine Receptor Binding but Structurally Alters the Ryanodine Receptor·Calmodulin Complex.

Authors:  Robyn T Rebbeck; Florentin R Nitu; David Rohde; Patrick Most; Donald M Bers; David D Thomas; Razvan L Cornea
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.